PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells)

By / 11/09/2023

PeproMene Bio, Inc. announced that the first dose cohort of its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma clinical trial of PMB-CT01 has been completed.